Is there a role for immunotherapy in ovarian cancer?

Epithelial ovarian cancer (OC) is the most lethal gynaecological malignancy worldwide with 22,530 estimated new cases in 2019, 13,980 deaths in 2019 and a median overall survival (OS) of less than 5 years (1). Indeed most of the cases are diagnosed in advanced stage and despite optimal management with a combination of surgery and platinum-base chemotherapy, most patients recur (2). The introduction of PARP inhibitors in treatment algorithms, has changed prognosis above all of BRCA mutated and homologous recombination deficient (HRD) positive patients but recurrence is still associated with development of drug resistance (and above all platinum resistance), low response rate to subsequent therapies and eventually death (2).